VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
LIVN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
LIVNLivaNova PLC
$83.62$4.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

LIVN logoLivaNova PLC(LIVN)Earnings, Financials & Key Ratios

LIVN•NASDAQ
$82.48
Price updated Jul 2, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryNeuromodulation and neuro devices
AboutLivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.Show more
  • Revenue$1.39B+10.7%
  • EBITDA$241M+34.0%
  • Net Income-$243M-483.5%
  • EPS (Diluted)-4.45-483.6%
  • Gross Margin67.71%-2.5%
  • EBITDA Margin17.39%+21.0%
  • Operating Margin14.37%+39.5%
  • Net Margin-17.47%-446.3%
  • ROE-19.24%-495.3%

LIVN Price & Volume

LivaNova PLC (LIVN) stock price & volume — 10-year historical chart

Loading chart...

Accelerating Revenue Growth Faces Persistent Margin Headwinds

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Accelerating
Profitability:Strained
Financial:Mixed
Cash Flow:Mixed
Primary Risk:Legacy litigation and impairments

Key Thesis Takeaways

  • LivaNova is currently navigating a transition phase where accelerating top-line growth, evidenced by a 14.3% year-over-year revenue increase in 2026Q1, is being offset by persistent challenges in scaling operating expenses.
  • While the company has successfully reduced its total debt to $334.5 million, structural balance sheet pressures remain due to $1.1 billion in negative retained earnings.
  • Investors should monitor whether the company can translate its specialized medical device adoption into consistent free cash flow, which currently remains volatile with a marginal 0.3% margin as of 2026Q1.

Verdict Logic

while the company has successfully deleveraged to a 0.28 debt-to-equity ratio, the lack of consistent free cash flow conversion and persistent negative retained earnings of $1.1 billion warrant a cautious wait-and-see approach.

LIVN Growth Metrics

LivaNova PLC (LIVN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years16.89%
5 Years8.24%
3 Years10.75%
TTM12.4%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM148.23%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM147.92%

Return on Capital

10 Years-2.25%
5 Years1.71%
3 Years4.33%
Last Year10.19%

LIVN Recent Earnings

LivaNova PLC (LIVN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 6, 2026
Metric
Actual
Est
EPS
$0.98+15.3%
$0.85
Rev
$362M+4.7%
$346M
Q1 2026
Feb 25, 2026
Metric
Actual
Est
EPS
$0.86+7.5%
$0.80
Rev
$361M+2.1%
$353M
Q4 2025
Nov 5, 2025
Metric
Actual
Est
EPS
$1.11+20.8%
$0.92
Rev
$358M+4.4%
$343M
Q3 2025
Aug 6, 2025
Metric
Actual
Est
EPS
$1.05+25.0%
$0.84
Rev
$353M+3.0%
$342M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 6, 2026
$0.98vs $0.85+15.3%
$362Mvs $346M+4.7%
Q1 2026Feb 25, 2026
$0.86vs $0.80+7.5%
$361Mvs $353M+2.1%
Q4 2025Nov 5, 2025
$1.11vs $0.92+20.8%
$358Mvs $343M+4.4%
Q3 2025Aug 6, 2025
$1.05vs $0.84+25.0%
$353Mvs $342M+3.0%
Based on last 12 quarters of dataView full earnings history →

Latest LIVN News

Recent stock market news and headlines for LivaNova PLC (LIVN)

Business Wire·Jun 24, 2026
LivaNova to Announce Second-Quarter 2026 Results

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2026 results on Wed., Aug. 5, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To lis.

Zacks Investment Research·Jun 17, 2026
LivaNova Reports Improved OSA Outcomes With PolySync Programming

LIVN's PolySync data show an 84.5% AHI response rate in OSA patients, building on OSPREY results for its aura6000 System.

Business Wire·Jun 16, 2026
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced new data showing that use of its PolySync™ programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe Obstructive Sleep Apnea (OSA) when treated with proximal hypoglossal nerve stimulation (pHGNS). The findings were presented at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societie.

Peers Comparison

Key metrics vs top competitors for LivaNova PLC (LIVN)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LIVN logoLIVNLivaNova PLCCurrent
$82.48$4.53B-18.5310.74%-17.47%-19.24%—
NVCR logoNVCRNovoCure Limited
$15.78$1.8B-12.938.28%-25.66%-50.82%—
INVA logoINVAInnoviva, Inc.
$21.90$1.62B6.6418.52%118.91%47.59%—
GKOS logoGKOSGlaukos Corporation
$137.57$8.05B-41.9432.33%-34.34%-26.46%—
MDT logoMDTMedtronic plc
$79.20$101.68B21.238.43%13.2%9.78%—
ABT logoABTAbbott Laboratories
$92.16$160.53B24.775.67%13.91%12.09%—

Compare LIVN vs Peers

LivaNova PLC (LIVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for LIVN.

Scale Benchmark

vs ABT

Larger-name benchmark to compare LIVN against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, INVA, GKOS, MDT

LIVN SEC Filings & Documents

LivaNova PLC (LIVN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Feb 25, 2026·SEC

Material company update

Jan 14, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 25, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

Get notified when LIVN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LIVN Frequently Asked Questions

LivaNova PLC (LIVN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is LivaNova PLC's revenue?

LivaNova PLC (LIVN) reported $1.43B in revenue for fiscal year 2025. This represents a 143248% increase from $1.0M in 1995.

How fast is LivaNova PLC growing?

LivaNova PLC (LIVN) grew revenue by 10.7% over the past year. This is steady growth.

Is LIVN profitable?

Yes, LivaNova PLC (LIVN) is profitable, generating $107.1M in net income for fiscal year 2025 (-17.5% net margin).

Dividend & Returns
What is LIVN's return on equity?

LivaNova PLC (LIVN) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

What is LivaNova PLC's free cash flow?

LivaNova PLC (LIVN) generated $161.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in LIVN back in 1995?

Total return calculator · dividends reinvested · 31+ years of data

See returns →